Pamela Tannenbaum

Affiliations: 
Merck Neuroscience, New Brunswick, NJ, United States 
Area:
Behavioral Neuroendocrinology
Google:
"Pamela Tannenbaum"
Mean distance: 17.23 (cluster 7)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gotter AL, Forman MS, Harrell CM, et al. (2016) Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Scientific Reports. 6: 27147
Kuduk SD, Skudlarek JW, DiMarco CN, et al. (2015) Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties. Bioorganic & Medicinal Chemistry Letters. 25: 2488-92
Roecker AJ, Mercer SP, Bergman JM, et al. (2015) Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters
Raheem IT, Breslin MJ, Bruno J, et al. (2015) Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters. 25: 444-50
Roecker AJ, Reger TS, Mattern MC, et al. (2014) Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorganic & Medicinal Chemistry Letters. 24: 4884-90
Gotter AL, Garson SL, Stevens J, et al. (2014) Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. Bmc Neuroscience. 15: 109
Tannenbaum PL, Stevens J, Binns J, et al. (2014) Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Frontiers in Behavioral Neuroscience. 8: 182
Kuduk SD, Skudlarek JW, Di Marco CN, et al. (2014) Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorganic & Medicinal Chemistry Letters. 24: 1784-9
Roecker AJ, Mercer SP, Schreier JD, et al. (2014) Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Chemmedchem. 9: 311-22
Ramirez AD, Gotter AL, Fox SV, et al. (2013) Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Frontiers in Neuroscience. 7: 254
See more...